What is the 13F Pro Quality Score for KRYS?

13F Pro ranks Krystal Biotech, Inc. (KRYS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KRYS's current score at https://13fpro.ai/research/KRYS (free sign-up required for the full ranking).

Which hedge funds own the most KRYS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KRYS include FMR, BlackRock,, Avoro Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/KRYS as soon as new 13F filings post.

Where does 13F Pro source KRYS data?

All Krystal Biotech, Inc. fundamentals and ownership data come directly from SEC EDGAR. Krystal Biotech, Inc. files with the SEC under CIK 1711279. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KRYS in?

Krystal Biotech, Inc. (KRYS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives KRYS's revenue?

Per Krystal Biotech, Inc.'s latest 10-Q filed with the SEC on 2026-05-04, the biggest revenue drivers are: United States ($87.5M, flat YoY); Europe ($20.7M, new in 2026); Japan ($8.2M, new in 2026). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/KRYS.

What are KRYS's largest expenses?

Krystal Biotech, Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($41.0M, +26% YoY); Research and development ($15.3M, +8% YoY); Cost of goods sold ($6.3M, +26% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is KRYS research updated on 13F Pro?

KRYS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Krystal Biotech, Inc.(KRYS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1711279 KRYS stock profile & AI dashboard →

13F Pro Quality Score

75.9/100

Rank #116 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.7/100

Profitability

95.0/100

Balance Sheet

93.7/100

Earnings Quality

30.0/100

Free Cash Flow

91.9/100

Institutional Flow

70.9/100

Revenue Scale

33.4/100

Dilution Risk

13.0/100

KRYS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Krystal Biotech, Inc. (KRYS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRYS at 75.9/100 on a 32-signal composite quality model, placing it at rank #116 of 2,879 stocks — the top 5% of the AI-ranked universe. KRYS scores in the top quartile across profitability (95.0), balance sheet strength (93.7), free cash flow (91.9). Areas of concern include earnings quality (30.0) and revenue scale (33.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Krystal Biotech, Inc. reports quarterly revenue of $116.4M, net income of $55.9M, an operating margin of 46.1%. Top institutional holders of KRYS by reported 13-F value include FMR, BlackRock,, Avoro Capital Advisors, based on the most recent SEC filings. KRYS trades on the Nasdaq exchange and files with the SEC under CIK 1711279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Krystal Biotech, Inc. directly from SEC EDGAR. Krystal Biotech, Inc.'s 13F Pro composite quality score has ranged between 8 and 86 since 2024, currently 75.9 — an improving long-term trajectory across 44 quarterly and live scoring snapshots.

✦

Fun facts about Krystal Biotech, Inc.

Quirks, history, and lore behind KRYS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the hundreds of millions of dollars — remarkable for a company that only recently transitioned from clinical-stage to commercial in a matter of a few years.
3
The History
Founded in 2016, it moved unusually fast from startup to approved product, built around a proprietary gene therapy delivery platform using modified herpes simplex virus vectors.
4
The Secret
Unlike most gene therapy players chasing one-and-done injections, this company's approach delivers treatment topically — straight to the skin — which is a genuinely weird flex in the gene therapy world.
5
The Lore
Its lead product targets dystrophic epidermolysis bullosa — a devastating rare skin disease nicknamed "butterfly skin" — giving patients something they'd never had before: an actual approved treatment.
6
The Giveaway
Its FDA-approved gel Vyjuvek is the first-ever redosable gene therapy, and the company's name sounds like it belongs in a fantasy novel but is spelled with a K and a Y.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving KRYS's Business? Latest 10-Q Breakdown

AI-extracted from Krystal Biotech, Inc.'s 10-Q filed 2026-05-04 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Krystal Biotech reported Q1 2026 product revenue of $116.4M, up 32% YoY, driven by VYJUVEK sales growth in Europe and Japan following launches in August 2025 and October 2025.

Biggest Revenue Drivers

Total revenue: $116.4M+32% YoY

United States$87.5Mflat YoY

Continued VYJUVEK sales in U.S. market maintained prior year level

Europe$20.7Mnew in 2026

VYJUVEK launched in Germany in August 2025 and France in October 2025 under early reimbursed access program

Japan$8.2Mnew in 2026

VYJUVEK launched in October 2025 following successful pricing completion with Japanese reimbursement authorities

Largest Expense Items

Selling, general and administrative$41.0M+26% YoY

Increase driven by $3.8M in payroll costs, $2.3M in global commercialization efforts, and $2.0M in professional services including legal and consulting fees

Research and development$15.3M+8% YoY

Increase primarily from $0.9M in unallocated materials and $0.8M in R&D payroll driven by production runs for KB111, KB407, and KB803, partially offset by decrease in B-VEC

Cost of goods sold$6.3M+26% YoY

Increase reflects higher units of VYJUVEK sold during the period

Watch Items from the Filing

Customer A represents 62% of accounts receivable as of March 31, 2026 (66% at year-end 2025), indicating significant concentration risk in VYJUVEK distribution channel.
DOJ subpoena received in Q1 2025 regarding sponsored genetic testing program and commercial practices; outcome unpredictable with potential material impact on results of operations.
September 2025 derivative stockholder lawsuit regarding director compensation settled in principle; final agreement and court approval pending; estimated settlement amount not material to financial statements.
Company has $823.4M in cash and investments as of March 31, 2026 and believes sufficient to fund operations for at least 12 months; profitability achieved with $55.9M net income in Q1 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$116.4M

Net Income

Q1 2026

$55.9M

Free Cash Flow

Q1 2026

$73.2M

Operating Margin

Q1 2026

46.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+33.9% YoY

$389.1MFY 2025

FY22 $0.00FY23 $50.7MFY24 $290.5MFY25 $389.1M

Net Income

+129.7% YoY

$204.8MFY 2025

FY22 $-140.0MFY23 $10.9MFY24 $89.2MFY25 $204.8M

Operating Income

+145.3% YoY

$161.3MFY 2025

FY22 $-145.2MFY23 $-109.6MFY24 $65.7MFY25 $161.3M

EPS (Diluted)

+128.0% YoY

$6.84FY 2025

FY22 $-5.49FY23 $0.39FY24 $3.00FY25 $6.84

Total Assets

+26.3% YoY

$1.33BFY 2025

FY22 $558.5MFY23 $818.4MFY24 $1.06BFY25 $1.33B

Op. Cash Flow

+62.7% YoY

$200.9MFY 2025

FY22 $-100.6MFY23 $-88.8MFY24 $123.4MFY25 $200.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2018	FY 2017
Revenue	$389.1M +33.9%	$290.5M +473.0%	$50.7M	$0.00	—	—
Net Income	$204.8M +129.7%	$89.2M +715.6%	$10.9M +107.8%	$-140.0M -1185.5%	$-10.9M -37.5%	$-7.9M
Operating Income	$161.3M +145.3%	$65.7M +160.0%	$-109.6M +24.5%	$-145.2M -1118.5%	$-11.9M -149.7%	$-4.8M
EPS (Diluted)	$6.84 +128.0%	$3.00 +669.2%	$0.39 +107.1%	$-5.49	—	—
Total Assets	$1.33B +26.3%	$1.06B +29.0%	$818.4M +46.5%	$558.5M +380.9%	$116.1M +131.7%	$50.1M
Operating Cash Flow	$200.9M +62.7%	$123.4M +239.0%	$-88.8M +11.7%	$-100.6M -964.8%	$-9.4M	—

AI Insight: KRYS Financial Trends

Krystal Biotech delivers 66% revenue growth and sixfold operating income expansion over eight quarters, with Q1 2026 setting records across all key metrics.

• Revenue grew from $70M in Q2 2024 to $116M in Q1 2026, a 66% increase over eight quarters with no quarterly decline.

• Operating income expanded from $9M in Q2 2024 to $54M in Q1 2026, with operating margin rising from ~13% to ~47%.

• Operating cash flow surged to $80M in Q1 2026, the highest in the dataset, recovering sharply from a negative $4M in Q2 2024.

• Equity compounded from $839M in Q2 2024 to $1,277M in Q1 2026, reflecting consistent retained earnings accumulation with no visible debt load.

⚠ Net income jumped to $79M in Q3 2025 then fell to $51M in Q4 2025 and $56M in Q1 2026 — the Q3 spike warrants scrutiny for one-time items.

⚠ Total debt data is absent across all periods; any future leverage introduction could materially alter the balance-sheet picture.

⚠ Sequential revenue growth is decelerating — Q3-to-Q4 2025 gain was $9M versus $18M the prior year — worth monitoring for signs of market saturation.

AI Insight: KRYS Ratio Trends

Krystal Biotech's operating margin hit 46.1% in Q1 2026, the highest single-quarter level in the dataset, while ROIC climbed to 16.8% — signaling sustained commercial momentum for Vyjuvek.

• Operating margin expanded dramatically from 12.2% in Q2 2024 to 46.1% in Q1 2026, reflecting strong operating leverage as revenue scaled.

• ROIC surged from 4.1% in Q2 2024 to 16.8% in Q1 2026, indicating increasingly efficient capital deployment over six quarters.

• ROA improved from 6.8% in Q2 2024 to 16.0% in Q1 2026, consistent with a maturing, asset-light commercial-stage business.

⚠ Q3 2025 NPM spiked to 81.2% versus ~40–50% in surrounding quarters, suggesting a one-off gain; sustainability of net income quality warrants scrutiny.

⚠ D/E is unavailable across all periods, leaving leverage and balance-sheet risk unassessable — a gap investors should independently verify.

⚠ ROE dipped from 19.2% in Q4 2024 to 14.5% in Q1 2025 before partially recovering to 17.5% in Q1 2026 — quarter-to-quarter volatility remains elevated.

Get alerted when KRYS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Krystal Biotech, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KRYS

FMR LLC
$1.1B4,373,987 sh
BlackRock, Inc.
$1.0B3,940,456 sh
Avoro Capital Advisors LLC
$746.3M2,888,888 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$376.3M1,456,727 sh
STATE STREET CORP
$339.5M1,314,434 sh
VANGUARD CAPITAL MANAGEMENT LLC
$301.0M1,165,324 sh
Soleus Capital Management, L.P.
$297.9M1,153,087 sh
Capital World Investors
$213.0M824,720 sh
Redmile Group, LLC
$174.0M673,505 sh
GEODE CAPITAL MANAGEMENT, LLC
$166.4M643,975 sh

Fund	Value	Shares
FMR LLC	$1.1B	4,373,987
BlackRock, Inc.	$1.0B	3,940,456
Avoro Capital Advisors LLC	$746.3M	2,888,888
VANGUARD PORTFOLIO MANAGEMENT LLC	$376.3M	1,456,727
STATE STREET CORP	$339.5M	1,314,434
VANGUARD CAPITAL MANAGEMENT LLC	$301.0M	1,165,324
Soleus Capital Management, L.P.	$297.9M	1,153,087
Capital World Investors	$213.0M	824,720
Redmile Group, LLC	$174.0M	673,505
GEODE CAPITAL MANAGEMENT, LLC	$166.4M	643,975

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KRYS on your watchlist

Track score changes the day Krystal Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KRYS a good stock to buy?

13F Pro's AI-powered analysis of Krystal Biotech, Inc. (KRYS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KRYS are available on the KRYS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KRYS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KRYS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Krystal Biotech, Inc.'s investment landscape.